Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

07.02.2019 | case report

The path of an esophageal carcinoma patient from curative to palliative treatment

We hereby report the course and management of a patient with human epidermal growth factor receptor 2 negative esophageal cancer who received neoadjuvant chemoradiation, surgical resection and subsequently palliative therapy for recurrent disease.

MD Ercan Müldür, Karl Mayrhofer, Wolfgang Hilbe

29.01.2019 | review

Surgical concepts in esophageal cancer

Despite neoadjuvant treatment being available for esophageal cancer, surgery remains the cornerstone of treatment. The aim of this article is to give a clear and simple overview of current issues in the available surgical strategies relating to …

Dr. Paolo Nicola Camillo Girotti, Prim. Prof. Dr. Ingmar Königsrainer

29.01.2019 | case report

Solitary scalp metastatic lesion as a sign of breast cancer recurrence—a case report

Being the most commonly diagnosed cancer in women, breast cancer is the second leading cause of cancer deaths among women in the United States [ 1 ]. With an incidence exceeding 20%, metastatic cutaneous lesions are more often found in women with …

MD Ahmed A. M. Abdelhafeez, MD Wael Ibrahim, MD Wessam Elsherief

24.01.2019 | review Open Access

ESMO 2018—personal highlights

This article intends to summarize personal highlights of the ESMO (European Society for Medical Oncology) 2018 meeting and does not aim to give a comprehensive overview. We will summarize the most recent presented data on the treatment of …

Isabel Heidegger, Wolfgang Hilbe, Andreas Pircher

23.01.2019 | short review Open Access

An update on immunotherapy in breast cancer

While immunotherapy (IOT) with monoclonal antibodies has long been present in HER2-positive breast cancer, the development of modern IOT concepts such as PD-1/PD-L1 targeting immune checkpoint inhibitors has been slow compared with other …

Rupert Bartsch, Elisabeth Bergen, Arik Galid

22.01.2019 | short review Open Access

Role of immune checkpoint inhibitors in gastrointestinal cancer treatment

In this short review we aim to summarize the role current clinical role of immunotherapy in particular of immune checkpoint inhibition in gastrointestinal malignancies and highlight the most important clinical trials.

MD Jakob Michael Riedl, MD Michael Stotz, MD, MBA Associate Professor of Medicine Armin Gerger

16.01.2019 | review

Current lymphoma diagnostic standards: the pathologists’ view

This short review aims at summarizing the current standards of lymphoma diagnostics and some novelties in the recent WHO classification. The importance of close collaboration between clinicians and pathologists to render the correct diagnosis and …

Magdalena M. Gerlach, Prof. Dr. Alexandar Tzankov

15.01.2019 | original report

Investigation of seasonal frequency and pathogens in febrile neutropenia

Febrile neutropenia (FEN) is the most common complication requiring hospitalization and causing mortality in patients with hematological cancer. Also, febrile episodes prolong the duration of hospitalization in neutropenic patients [ 1 ].

Seray Karagöz Özdemir, Utku Iltar, Ozan Salim, Orhan Kemal Yücel, Ramazan Erdem, Özge Turhan, Levent Undar

07.01.2019 | original report

Changes in patients’ quality of life during radiotherapy and 1 month after treatment

The EORTC QLQ-30 quality of life (QOL) questionnaire is designed to measure cancer patients’ physical, psychological, and social functions [ 1 – 8 ]. Cancer therapy can be of long duration, and QOL often decreases during this time period. Because …

M.D. Osamu Tanaka, N.S. Yuka Kunishima, M.P. Takuya Taniguchi, M.P. Kousei Ono, M.D. Masayuki Matsuo

21.12.2018 | review

Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls

Immunochemotherapy has long been the backbone of all treatment for B‑cell non-Hodgkin lymphoma. These therapies led to long-term disease control or even cure for some patients. However, these treatments also caused—sometimes severe—toxicities and …

MD Thomas Spanberger

05.12.2018 | comment

Demystification of palliative care. In regard to Masel and Kreye

Andrés Vargas

05.12.2018 | short review Open Access

Therapeutic endoscopic strategies in early esophageal cancer and dysplastic Barrett’s epithelium

Endoscopic therapy is the gold standard for curative treatment of early esophageal adenocarcinoma (EAC) including dysplastic Barrett´s epithelium (BE) and very early squamous cell carcinoma (SCC) because it is superior to surgery in regard to …

Teresa Fritz, Rainer Schöfl, Friedrich Wewalka, Alexander Ziachehabi

23.11.2018 | short review Open Access

Radiochemotherapy in esophageal cancer

Esophageal cancer is one of the ten most frequent tumors worldwide. There are two major histologies: squamous cell carcinomas, which appear more frequently in the upper part of the esophagus, and adenocarcinomas, which are predominantly found in …

Elke Mayer, Christoph Reinhold Arnold, Ute Ganswindt, Robert Jäger

19.11.2018 | short review

Diffuse large B‑cell lymphoma

Since the introduction of anti-CD20 antibodies and polychemotherapy, diffuse large B‑cell lymphoma (DLBCL) has become a treatable, and, for a high proportion of patients, curable disease. However, a sizeable proportion of patients, especially in …

David Fuchs

19.11.2018 | educational

Educational no. 4: PCR-based methods

For decades, polymerase chain reaction (PCR) has been playing a fundamental role in hematology. Not only in diagnostics, but also in follow-up and therapeutic decision-making, PCR impacts the treatment of patients with neoplastic diseases. In this …

Priv. Doz. Mag. Dr. Otto Zach

19.11.2018 | short review Open Access

A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors

In this report, we present the medical history of a 30-year-old male patient with HER2- and PD-L1-negative metastasized adenocarcinoma of the gastric cardia, who received three cycles of pembrolizumab (200  mg every 2 weeks) after the failure of …

Hossein Taghizadeh, Katharina Lampichler, Andrea Beer, Matthias Preusser, MD, PhD Aysegul Ilhan-Mutlu

11.10.2018 | case report

Kaposi sarcoma following autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia

Kaposi sarcoma (KS) is a low grade angioproliferative disorder thought to be derived from endothelial cell lineage that requires infection with human herpes virus 8 (HHV-8) for its development. This condition carries a variable clinical course …

M.D Utku Iltar, Vedat Aslan, Mesut Gocer, Fatma Aykac, İlknur Nizam, Mehmet Çelik, Faruk Gulec, Turgay Ulaş, Erdal Kurtoğlu

20.09.2018 | case report

Central nervous system-predominant Erdheim–Chester disease mimicking meningioma responding to BRAF inhibitor therapy: the importance of molecular diagnosis and targeted therapy in rare neoplastic disorders

Erdheim–Chester disease (ECD) is a rare multi-system, non-Langerhans cell histiocytic disorder (NLCHD) with only a few hundred cases reported in the literature. Its diverse clinical manifestations require a high level of diagnostic suspicion.

MBBS, DNB Amrita Chakrabarti, MBBS, MCH Anirban Deep Banerjee, MBBS, MD Ishani Mohapatra, MBBS, MD Ritesh Sachdev, MBBS, MD Bosky Jain, MBBS, MD, FRCPath Nitin Sood